Halberd(OTC) HALB

Current Price$0.00

Market Cap$515.90K

Since IPO (2009)-99%

5 Year-96%

1 Year-57%

1 Month+11%

Halberd last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-24

Halberd stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+42.86%	USD 0.00	2026-07-17
1 month	+11.11%	USD 0.00	2026-06-22
3 month	-4.76%	USD 0.00	2026-04-24
Year to date	-33.33%	USD 0.00	2025-12-31
1 year	-56.52%	USD 0.00	2025-07-24
3 year	-89.04%	USD 0.01	2023-07-25
5 year	-95.97%	USD 0.02	2021-07-23
Since inception	-99%	USD 0.10	2009-06-25

Halberd Financials at a Glance

Market Cap

$515.90K

Revenue (TTM)

$0.00

Net Income (TTM)

-$44.49K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.17 (Low)

Dividend

$0.00

Beta (Volatility)

0.17 (Low)

Price

$0.00

Volume

1,900,300

Open

$0.00

Price

$0.00

Volume

1,900,300

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.17 (Low)

Price

$0.00

Volume

1,900,300

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

HALB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Halberd

Halberd Corporation is a biotechnology firm focused on developing innovative therapies for neurodegenerative conditions. The company addresses serious illnesses such as PTSD, CTE, Alzheimer's, and various cancers, aiming to improve patient outcomes through advanced treatment options.

Products and Services

Therapeutic solutions for neurodegenerative diseases
Research initiatives targeting PTSD and CTE
Innovative treatments for various forms of cancer

Growth Outlook

Established in 2009, with a strong focus on research and development
Potential market expansion in the growing biotechnology sector
Continued investment in innovative therapies to meet unmet medical needs

Financial Highlights

Recent quarterly net income of -$24,417, reflecting ongoing investment in R&D
Trailing twelve months (TTM) revenue of $0, indicating a focus on development rather than sales
Current liabilities of $728,261, highlighting the need for strategic financial management

Halberd Corporation operates in a challenging yet promising sector, with a commitment to addressing critical health issues. The company's focus on research and development positions it well for future growth, despite current financial challenges. The absence of revenue in recent quarters underscores the emphasis on long-term innovation over immediate profitability. Investors may find interest in the potential for breakthroughs in treatment options that could significantly impact the biotechnology landscape.

AI Generated • Jul 1, 2026

Industry

Biotechnology

Sector

Health Care

CEO

William A. Hartman

Website

halberdcorporation.com

Headquarters

Jackson Center, PA 16133, US

HALB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

5.01%

Return on Capital

N/A

Return on Assets

-1079.88%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$515.90K

Shares Outstanding

515.88M

Volume

1.90M

Avg. Volume

793.25K

Financials (TTM)

Gross Profit

-$549.00

Operating Income

-$40.27K

EBITDA

-$39.72K

Operating Cash Flow

-$110.18K

Capital Expenditure

$0.00

Free Cash Flow

-$110.18K

Cash & ST Invst.

$0.00

Total Debt

$150.00K

Halberd Performance Analysis

Halberd annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-07-31	USD 8,020	53.1%
2023	2023-07-31	USD 2,725	-66.0%
2024	2024-07-31	USD 999	-63.3%
2025	2025-07-31	USD 0	N/A

Halberd sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-04-30	N/A
Q4	2025-07-31	N/A
Q1	2025-10-31	N/A
Q2	2026-01-31	N/A

Halberd annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-07-31	USD -0.00	45.5%
2023	2023-07-31	USD -0.00	-75.0%
2024	2024-07-31	USD -0.00	-87.5%
2025	2025-07-31	USD 0.00	N/A

Halberd sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-04-30	N/A
Q4	2025-07-31	N/A
Q1	2025-10-31	N/A
Q2	2026-01-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$183.00

+0.0%

Gross Margin

0.00%

N/A

Market Cap

$515.90K

N/A

Market Cap/Employee

$171.97K

N/A

Employees

N/A

Net Income

-$24.42K

-704.2%

EBITDA

-$22.83K

-700.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$0.00

-100.0%

Total Debt

$150.00K

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$150.00K

+0.0%

Short Term Debt

$0.00

N/A

Return on Assets

-10.80%

N/A

Return on Invested Capital

5.56%

N/A

Free Cash Flow

-$530.00

+98.9%

Operating Cash Flow

-$531.00

+98.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HXBMHelix BioMedix, Inc.

HXBMHelix BioMedix, Inc.$1.79+0.00%

BPTHBio-Path Holdings, Inc.

BPTHBio-Path Holdings, Inc.$0.04+0.00%

NTRRNeutra Corp.

NTRRNeutra Corp.$0.00+0.00%

MRZMMarizyme, Inc.

MRZMMarizyme, Inc.$0.00+0.00%

EVFMEvofem Biosciences, Inc.

EVFMEvofem Biosciences, Inc.$0.01-4.76%

ORGSOrgenesis Inc.

ORGSOrgenesis Inc.$0.40+0.00%

ISCOInternational Stem Cell Corporation

ISCOInternational Stem Cell Corporation$0.31+10.71%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About HALB

What is the current price of Halberd?

Halberd is trading at $0.00 per share.

What is the 52-week range for Halberd?

Over the past 52 weeks, Halberd has traded between $0.00 and $0.00.

How much debt does Halberd have?

As of the most recent reporting period, Halberd reported total debt of $150.00K.

How much cash does Halberd have on hand?

Halberd reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Halberd’s dividend yield?

Halberd does not currently have a dividend yield.

Halberd(OTC) HALB

Halberd Financials at a Glance

HALB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Halberd

HALB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Halberd Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HALB

What is the current price of Halberd?

What is the 52-week range for Halberd?

How much debt does Halberd have?

How much cash does Halberd have on hand?

What is Halberd’s dividend yield?

Premium Investing Services